Study of Eltrombopag in Platelet Refractory Thrombocytopenia

This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia
(low platelet count). Eltrombopag is approved by the FDA for the treatment of
thrombocytopenia (low platelet count) in adults who have had an insufficient response to
medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the
FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to
platelet transfusion and so for this study is considered investigational.